Inspection Record

New Vitalis Pharmacy LLC dba New Vitalis Pharmacy — FDA 483 Findings

US FDAInspected 2021-08-27Published 2022-03-09 7 findingsContamination controlEquipment and facilityTraining and personnelAseptic processing and sterility assurance

Inspectors Lauren N Howard · Carl A HuffmanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

Personnel did not disinfect to prevent contamination.

2Contamination control

Non-microbial contamination was observed in your production area.

3Equipment and facility

Vermin was observed in an area immediately adjacent to your production area.

4Contamination control

You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.

5Training and personnel

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

6Aseptic processing and sterility assurance

Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

7Equipment and facility

HEPA filters were not sealed around each perimeter to the support frame.

About this record

Extracted automatically from the document US FDA published on 2022-03-09. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

New Vitalis Pharmacy LLC dba New Vitalis Pharmacy company profile — full history US FDA documents, 2022 Go to Findings search